Introduction {#sec1}
============

Substituted imidazopyridines represent an important class of fused heterocyclic compounds owing various pharmacological properties.^[@ref1]^ Their analogues have been successfully used for pharmaceutical chemistry as well as in materials science.^[@ref2]^ Marketed drugs like alpidem,^[@ref3]^ zolpidem,^[@ref4]^ nicopidem and saripidem,^[@ref5]^ minodronic acid,^[@ref6]^ and optically active GSK812397 drug^[@ref7]^ are derived from the imidazo\[1,2-*a*\]pyridine scaffold ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref8]^

![Imidazo\[1,2-*a*\]pyridine-derived drugs.](ao-2019-000359_0001){#fig1}

The construction of new C--N,^[@ref9]^ C--S,^[@ref10]^ and C--O^[@ref11]^ bonds into organic molecules is highly appreciable in modern chemistry. Although in recent times a variety of substitutions on imidazopyridines have been made, there are no reports pertaining to a general approach for the synthesis of different C--X bonds at the C-3 methylene position of imidazo\[1,2-*a*\]pyridines. Recently, Hajra and group have presented the aminomethylation of imidazo-heterocycles with morpholine using (diacetoxyiodo)benzene, and Kumar et al. approached the synthesis by using *N*-methyl-morpholine oxide, which acts as a coupling partner as well as the oxidant.^[@ref12]^ Both of these strategies, however, suffer from limitations in the context of (a) use of morpholine as only amine, (b) not a general C--X bond approach, (c) requirement of halo-substituted imidazopyridines as starting materials, (d) harsh reaction conditions, and (e) low atom economy. In this context, we developed a BCl~3~-mediated general C--X bond formation method around imidazopyridines that involve nucleophilic substitution reactions with a diverse array of amines, thiols, and alcohols at the C-3 methylene position ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Summary of Work](ao-2019-000359_0002){#sch1}

Benzyl protection of a hydroxyl group is one of the most frequently used procedures in synthesis because of the mild conditions involved in its removal.^[@ref13]^ Lewis acid has long been widely used as an ether-cleaving reagent because of its tolerance of several other functional groups in the target molecule.^[@ref14]^

However, in the case of imidazopyridines, we presumed an aza-directed coupling with different nucleophiles through a resonance-stabilized intermediate **A**. In this perspective, we present BCl~3~-mediated different reactions of imidazopyridines **1** (synthesized as per our earlier approach)^[@ref15]^ against different N/S/O nucleophiles that helped to generate different valuable carbon heterobonds.

Results and Discussion {#sec2}
======================

We commenced our study with 3-((benzyloxy) methyl)-2-phenylimidazo\[1,2-*a*\]pyridine **1** (1.0 equiv) as the model substrate to find out the optimized reaction conditions as summarized in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. Initially, the reaction was performed using BCl~3~ (1 equiv) and piperidine (1 equiv) in dry dichloromethane (DCM) at −78 °C under a nitrogen atmosphere for 2 h. Under these conditions, **2a** was isolated in 12% yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). Considering the gradual decrease in molarity of BCl~3~ solution over time due to high volatility of BCl~3~, 1.4 equiv of BCl~3~ was used, an improvement in yield (32%) of the desired product **2a** (entry 2) was noticed.^[@ref16]^

###### Optimization of the Reaction Conditions[a](#t1fn1){ref-type="table-fn"}

![](ao-2019-000359_0004){#GRAPHIC-d7e345-autogenerated}

  entry   Lewis acid (equiv)           amine (equiv)   *T* \[°C\]   yields[b](#t1fn2){ref-type="table-fn"} of **2a** \[%\]
  ------- ---------------------------- --------------- ------------ --------------------------------------------------------
  1       BCl~3~ (1)                   1               --78         12
  2       BCl~3~ (1.4)                 1               --78         32
  3       BCl~3~ (1.4)                 2               --78         54
  4       BCl~3~ (1.4)                 3               --78         77
  **5**   **BCl**~**3**~**(1.4)**      **3**           **0**        **80**
  6       BCl~3~ (1.4)                 3               20           43
  7                                    3               0            0
  8       BF~3~·O(C~2~H~5~)~2~ (1.4)   3               --78         28
  9       BF~3~·O(C~2~H~5~)~2~ (1.4)   3               0            40
  10      BBr~3~ (1.4)                 3               --78         0
  11      BBr~3~ (1.4)                 3               0            18
  12      AlCl~3~ (1.4)                3               0            0

General conditions: **1** (0.3 mmol), Lewis acid (0.3 mmol), and piperidine (0.3 mmol), in DCM at −78 °C under N~2~ for 2 h.

Isolated yield.

Following improvised yield of **2a**, the reaction conditions particularly the change in the concentration of amine and variation in temperature were explored (entries 3--12). Primarily, screening of our reaction at different concentrations of amine against **1** was performed (entry 3 and 4), and the best result was observed with 3 equiv of amine (entry 4). In continuation, various reactions were conducted at different temperatures (entries 5--6). The reaction executed at 0 °C produced better yield as compared to reaction at 20 °C, indicating that 0 °C is an optimal temperature for this transformation. Further, in the absence of Lewis acid, no reaction was observed (entry 7). Subsequently, boron catalysts BF~3~O(C~2~H~5~)~2~ and BBr~3~ were also investigated in the presence of 3 equiv of piperidine (entries 8--10) at −78 °C and 0 °C, but BCl~3~ was found most appropriate in terms of yield (entry 5). Also, no product was observed in the case of AlCl~3~ (entry 12). Finally, the use of BCl~3~ (1.4 equiv) and amine (3 equiv) at 0 °C to room temperature (rt) under nitrogen was found to be the optimized reaction condition (entry 3).

With these optimized reaction conditions in hand, the scope of the C3-methylene amination was demonstrated by testing a wide variety of cyclic, acyclic, and aromatic amines. We were pleased to find that in all tested reactions, the desired C3-aminomethylated-imidazo\[1,2-*a*\]pyridines ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, entries **2a--2x**) were produced in good yields (68--88%). 3-((Benzyloxy)methyl)-2-phenylimidazo\[1,2-*a*\]pyridine **1** reacted efficiently with piperidine and morpholine, giving the corresponding product **2a** and **2c** in 80 and 74% yields, respectively, and pyrrolidine yielded product **2e** with comparable yield (70%).The presence of the electron-donating methyl group on imidazo\[1,2-*a*\]pyridines improved the yield to 82% (entries **2b** and **2d**). Reaction with aniline furnished product **2f** in excellent yield (86%). Besides C2-phenyl substitution, the scope and generality of the reaction was also investigated on C2 alkenylated and alkynated imidazo\[1,2-*a*\]pyridines^[@ref17]^ for amination, and these groups were well tolerated and afforded the products (entries **2g--2j**) in good yield (68--79%). In addition, different experiments were performed between 2-iodo-imidazo\[1,2-*a*\]pyridines and various amines to afford the desired products (entries **2h--2x**). In this case, yields were also good for all the reactions conducted irrespective of the nature of amine ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Reaction with piperidine (entry **2m**, 83% yield) and morpholine (entry **2o**, 76%) proceeded very smoothly and comparatively more reactive than pyrrolidine (entry **2l**, 75% yield). The presence of the methyl group on imidazo\[1,2-*a*\]pyridines further enhanced the yield up to 87% (entry **2n**) and chloro-substitution slightly decreased the yield (entry **2x**, 72%). Aniline and benzylamine were also checked and afforded products **2s** and **2t** in excellent yields (80 and 88%, respectively). The use of alkyne as a triazole precursor^[@ref18]^ encouraged us to perform reaction with propargyl amine and furnished the desired product **2u** in 87% yield without any difficulties. The reaction was also compatible with the secondary amine diethylamine (entries **2q** and **2r**) as well as the primary amine *n*-propyl amine (entry **2w**, 82% yield), while in the case of hexamethylene diamine (**2v**), an inseparable mixture was obtained. In general, we observed that irrespective the nature of imidazopyridines and amines, all of the tested reactions were efficiently transformed to desired products within 2 h.

###### C3-Methylene Amination of Imidazo\[1,2-*a*\]pyridines[a](#t2fn1){ref-type="table-fn"}^,^[b](#t2fn2){ref-type="table-fn"}

![](ao-2019-000359_0005){#GRAPHIC-d7e801-autogenerated}

![](ao-2019-000359_0006){#gr4}

Reaction conditions: **1** (0.3 mmol), BCl~3~ (0.42 mmol), and R~3~R~3~NH (0.9 mmol), in DCM at 0 °C to rt under N~2~ for 2 h.

Isolated yield.

To investigate the practicability of this method, another set of experiments were performed between imidazopyridine **1** and thiols under the optimized reaction conditions and yields were generally good for all tested reactions (entries **3a--3l**) ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). Various substituted aromatic and aliphatic thiols proceeded well in this process. 2-Mercaptopyridine smoothly underwent reaction with **1**, affording the desired product **3a** in 68% yield. Additionally, the electron-donating group on the aromatic ring of thiophenol enhances the yield of the desired product (entries **3b--3c**). Reaction with *n*-octyl mercaptan (entry **3d**) afforded the desired compound in good yield (64%). Moreover, 2-alkenyl (entry **3e**) and alkynyl (entry **3f**) substitution on **1** dropped the yield to 68 and 63%, respectively. Importantly, mono- and dihalogen-substituted thiophenols (entry **3i** and **3j**) worked well, thus providing an opportunity for additional modifications of products. Notably, 2-iodo-substituted imidazo\[1,2-*a*\]pyridine **1** was also a good substrate for this reaction system (entries **3g--3l**).

###### C--S Bond Formation of Imidazo\[1,2-*a*\]pyridines[a](#t3fn1){ref-type="table-fn"}^,^[b](#t3fn2){ref-type="table-fn"}

![](ao-2019-000359_0007){#GRAPHIC-d7e895-autogenerated}

![](ao-2019-000359_0008){#gr5}

Reaction conditions: **1** (0.3 mmol), BCl~3~ (0.42 mmol), and R~4~SH (0.9 mmol) in DCM at 0 °C under N~2~ for 2 h.

Isolated yields.

Next, we extended the method for the generation of different C--O bonds by treating different imidazo\[1,2-*a*\]pyridine **1** with different aliphatic alcohols as per the earlier optimal conditions and successfully isolated different products (entries **4a--4j**) in good yield (60--80%, [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}). As evident, despite change in the substitutions of **1**, we isolated the desired products in moderate to good yield (60--80%). However, reactions with 2-iodo substitutions (entries **4e--4i**) produced slightly better yields (68--80%). Furthermore, in these set of reactions, the change in the aliphatic alcohols as the coupling partner did not show a predominant effect in the reaction competence. We successfully isolated the desired products with most of the alcohols tested. However, we observed the best yields when reactions were conducted with methanol (entries **4a**, **4b**, **4e**, **4f**, and **4j**) and also found that increase in alkyl chain length of alcohol (entries **4g**, **4h**, and **4i**) and C-5 bromo substitution slightly decreased the yield.

###### C--O Bond Formation of Imidazo\[1,2-*a*\]pyridines[a](#t4fn1){ref-type="table-fn"}^,^[b](#t4fn2){ref-type="table-fn"}

![](ao-2019-000359_0009){#GRAPHIC-d7e980-autogenerated}

![](ao-2019-000359_0010){#gr6}

Reaction conditions: 1 (0.3 mmol), BCl~3~ (0.42 mmol), and R~5~OH (0.9 mmol), in DCM at 0 °C under N~2~ for 2h.

Isolated yield.

0--70 °C.

On the basis of our observation and previous reports,^[@ref18]^ a plausible mechanism is proposed in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. Probably, at the first step, 3-((benzyloxy)methyl)-2-phenylimidazo\[1,2-*a*\]pyridine **1** forms a complex with BCl~3~. This complex converts into intermediate **A** (supported by mass spectra) through aza-directed electronic delocalization. Subsequently, the intermediate **A** is readily coupled with nucleophiles to afford the desired compounds **2**/**3**/**4**.

![Plausible Reaction Mechanism](ao-2019-000359_0003){#sch2}

Conclusions {#sec3}
===========

In summary, BCl~3~-mediated methodologies around imidazo\[1,2-*a*\]pyridines for the generation of different C--N, C--S, and C--O bonds through an in situ debenzylation are presented. The reaction demonstrated a broad substrate scope and excellent functional group tolerance at mild reaction conditions. These methods furnished a wide variety of 3-amino/thio/alkoxy 2-iodo-imidazo\[1,2-*a*\]pyridines in good yields and are perhaps ascertained because of aza-directed unusual coupling with different nucleophiles.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

All reactions and purity of the synthesized compounds were monitored by Merck thin-layer chromatography (TLC) using silica gel 60 F254 aluminum plates (20 × 20 cm). Visualization was accomplished by UV spectrometry at 254 nm light and exposure to iodine vapors. Buchi rotavapor was used for concentration of organic solvents. Column chromatographic purifications were performed on silica gel (100--200 mesh) for compound purification. ^1^H and ^13^C NMR spectra in CDCl~3~ were recorded with 400 and 500 MHz NMR instruments, respectively, using (CH~3~)~4~Si as an internal standard. Chemical shifts (δ) are expressed in parts per million (ppm, scale) referenced to the residual solvent (i.e., ^1^H 7.24 ppm and ^13^C 77.1 ppm for CDCl~3~). MestReNova software was used to process NMR spectra. Signal multiplicity is expressed as follows: s (singlet), br s (broad singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). *J* values are given in hertz (Hz). Mass spectra were obtained by using a Q-TOF-LC/MS spectrometer using electron spray ionization. Unless otherwise indicated, materials and solvents were purchased and used without further purification. All starting compounds **1** (3-((benzyloxy)methyl)-2-iodoimidazo\[1,2-*a*\]pyridine, 3-((benzyloxy) methyl)-2-arylimidazo \[1,2-*a*\]pyridine, 3-((benzyloxy)methyl)-2-(phenylethynyl)imidazo\[1,2-*a*\]pyridine, and 3-((benzyloxy)methyl)-2-styrylimidazo\[1,2-*a*\]pyridine) were synthesized compared with the spectroscopic data by following the literature reports.^[@ref15]^

General Procedure for C3-Methylene C--N Bond Formation of Imidazo\[1,2-*a*\]pyridine (**2**) {#sec4.2}
--------------------------------------------------------------------------------------------

In a round-bottom flask, 3-((benzyloxy)methyl)-2-phenylimidazo\[1,2-*a*\]-pyridine **1** (0.3 mmol) was dissolved in dry DCM (2 mL) at 0 °C under a nitrogen atmosphere. A BCl~3~ solution (1.0 M in methylene chloride) (0.42 mmol) was slowly added, and complex formation was confirmed by TLC. After that, temperature of reaction was increased up to rt and an amine (0.9 mmol) was added and stirred for 2 h (reaction progress was monitored by TLC). After completion, the reaction was quenched by water to stop the reaction. The aqueous solution was extracted with DCM (3 × 10 mL). The combined organic layer was washed with brine, dried over anhydrous Na~2~SO~4~, and evaporated in vacuum. The residue was purified by a column (silica gel, 80/20 *n*-hexane/ethyl acetate) to give the desired product.

### 2-Phenyl-3-(piperidin-1-ylmethyl)imidazo\[1,2-*a*\]pyridine (**2a**) {#sec4.2.1}

Yield: (70 mg, 80%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.56 (d, *J* = 6.8 Hz, 1H), 7.83 (d, *J* = 7.2 Hz, 2H), 7.67 (d, *J* = 9.0 Hz, 1H), 7.50--7.47 (m, 2H), 7.41--7.38 (m, 1H), 7.28--7.23 (m, 1H), 6.87--6.84 (m, 1H), 4.02 (s, 2H), 2.48 (br s, 4H), 1.59 (dt, *J* = 10.7, 5.4 Hz, 4H), 1.47 (d, *J* = 4.6 Hz, 2H); ^13^C NMR (126 MHz, CDCl~3~): δ 145.08 (C), 134.51 (C), 128.93 (CH), 128.48 (CH), 127.75 (CH), 125.71 (CH), 124.72 (CH), 117.12 (CH), 111.91 (CH), 54.07 (CH~2~), 52.17 (CH~2~), 25.74 (CH~2~), 24.14 (CH~2~); ESI-HRMS (*m*/*z*): calcd for C~19~H~22~N~3~ \[M + H\]^+^, 292.1814; found, 292.1811.

### 6-Methyl-2-phenyl-3-(piperidin-1-ylmethyl)imidazo\[1,2-*a*\]pyridine (**2b**) {#sec4.2.2}

Yield: (75 mg, 82%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.24 (s, 1H), 7.81 (d, *J* = 7.3 Hz, 2H), 7.53 (d, *J* = 9.1 Hz, 1H), 7.46--7.42 (m, 2H), 7.36--7.33 (m, 1H), 7.06 (dd, *J* = 9.2, 1.4 Hz, 1H), 3.91 (s, 2H), 2.43 (s, 4H), 2.36 (s, 3H), 1.57--1.52 (m, 4H), 1.44 (d, *J* = 4.8 Hz, 2H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.75 (C), 144.08 (C), 134.89 (C), 128.90 (CH), 128.34 (CH), 127.56 (CH), 127.48 (CH), 123.19 (CH), 121.22 (C), 116.46 (CH), 54.20 (CH~2~), 52.44 (CH~2~), 26.04 (CH~2~), 24.39 (CH~2~), 18.50 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~20~H~24~N~3~ \[M + H\]^+^, 306.1970; found, 306.1964.

### 4-((2-Phenylimidazo\[1,2-*a*\]pyridin-3-yl)methyl)morpholine (**2c**)^[@ref12]^ {#sec4.2.3}

Yield: (65 mg, 74%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.44 (d, *J* = 6.9 Hz, 1H), 7.80 (d, *J* = 7.3 Hz, 2H), 7.65 (d, *J* = 9.0 Hz, 1H), 7.46 (d, *J* = 7.5 Hz, 2H), 7.39--7.35 (m, 1H), 7.25--7.20 (m, 1H), 6.85--6.81 (m, 1H), 3.98 (s, 2H), 3.69--3.65 (t, *J* = 4.8 Hz, 4H), 2.51--2.45 (t, *J* = 4.8 Hz, 4H); ^13^C NMR (101 MHz, CDCl~3~): δ 145.35 (C), 145.12 (C), 134.44 (C), 128.92 (CH), 128.49 (CH), 127.81 (CH), 125.34 (CH), 124.62 (CH), 117.32 (CH), 115.92 (C), 111.93 (CH), 67.01 (CH~2~), 53.23 (CH~2~), 52.15 (CH~2~). ESI-HRMS (*m*/*z*): calcd for C~18~H~20~N~3~O \[M + H\]^+^, 294.1606; found, 294.1605.

### 4-((6-Methyl-2-phenylimidazo\[1,2-*a*\]pyridin-3-yl)methyl)morp-holine (**2d**)^[@ref12]^ {#sec4.2.4}

Yield: (72 mg, 78%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.17 (s, 1H), 7.80 (d, *J* = 7.3 Hz, 2H), 7.55 (d, *J* = 9.1 Hz, 1H), 7.47--7.43 (m, 2H), 7.38--7.34 (m, 1H), 7.08 (dd, *J* = 9.1, 1.0 Hz, 1H), 3.95 (s, 2H), 3.70--3.66 (m, 4H), 2.51--2.47 (m, 4H), 2.38 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 145.07 (C), 144.12 (C), 134.51, 128.86 (CH), 128.45 (CH), 127.85 (CH), 127.71 (CH), 122.82 (CH), 121.58, 116.60 (CH), 115.67 (CH), 67.02 (CH~2~), 53.22 (CH~2~), 52.06 (CH~2~), 18.54 (CH~3~). ESI-HRMS (*m*/*z*): calcd C~19~H~22~N~3~O \[M + H\]^+^, 308.1763; found, 308.1761.

### 2-Phenyl-3-(pyrrolidin-1-ylmethyl)imidazo\[1,2-*a*\]pyridine (**2e**) {#sec4.2.5}

Yield: (58 mg, 70%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.50 (d, *J* = 6.9 Hz, 1H), 7.79 (dd, *J* = 5.2, 3.2 Hz, 2H), 7.64 (d, *J* = 9.1 Hz, 1H), 7.46 (dd, *J* = 10.3, 4.7 Hz, 2H), 7.37 (d, *J* = 6.1 Hz, 1H), 7.24--7.19 (m, 1H), 6.82 (dd, *J* = 6.7, 5.9 Hz, 1H), 4.14 (s, 2H), 2.55 (br s, 4H), 1.77--1.74 (m, 4H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.91 (C), 134.71 (C), 129.02 (CH), 128.92 (C), 128.48 (CH), 128.44 (C), 127.80 (C), 127.67 (CH), 125.44 (CH), 124.53 (CH), 117.20 (CH), 111.87 (CH), 53.68 (CH~2~), 48.61 (CH~2~), 23.60 (CH~2~). ESI-HRMS (*m*/*z*): calcd for C~18~H~20~N~3~ \[M + H\]^+^, 278.1657; found, 278.1654.

### *N*-((2-Phenylimidazo\[1,2-*a*\]pyridin-3-yl)methyl)aniline (**2f**) {#sec4.2.6}

Yield: (76 mg, 86%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.13 (d, *J* = 6.8 Hz, 1H), 7.78 (d, *J* = 7.1 Hz, 2H), 7.70 (d, *J* = 9.1 Hz, 2H), 7.46--7.43 (m, 2H), 7.38 (d, *J* = 7.3 Hz, 2H), 7.27--7.23 (m, 3H (merged with CDCl~3~)), 6.86--6.81 (m, 2H), 6.76 (d, *J* = 7.7 Hz, 2H), 4.70 (s, 4H); ^13^C NMR (101 MHz, CDCl~3~): δ 147.60 (C), 145.08 (C), 144.47 (C), 133.68 (C), 129.50 (CH), 128.80 (CH), 128.45 (CH), 128.16 (CH), 125.18 (CH), 124.18 (CH), 118.52 (CH), 117.51 (CH), 116.56 (C), 113.24 (CH), 112.70 (CH), 38.32 (CH~2~). ESI-HRMS (*m*/*z*): calcd for C~20~H~18~N~3~ \[M + H\]^+^, 300.1501; found, 300.1494.

### 4-((6-Methyl-2-styrylimidazo\[1,2-*a*\]pyridin-3-yl)methyl)morpholine (**2g**) {#sec4.2.7}

Yield: (71 mg, 71%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.99 (s, 1H), 7.64 (d, *J* = 15.9 Hz, 1H), 7.57 (d, *J* = 7.4 Hz, 2H), 7.50 (d, *J* = 9.2 Hz, 1H), 7.38--7.34 (m, 2H), 7.28--7.24 (m, 1H), 7.18 (d, *J* = 15.9 Hz, 1H), 7.06 (dd, *J* = 9.2, 1.6 Hz, 1H), 3.85 (s, 2H), 3.70--3.66 (m, 4H), 2.52--2.47 (m, 4H), 2.35 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.70 (C), 142.37 (C), 137.47 (C), 130.68 (CH), 128.67 (CH), 128.48 (CH), 127.67 (CH), 126.63 (CH), 122.47 (CH), 121.37 (C), 118.02 (CH), 117.01 (C), 116.16 (CH), 66.93 (CH~2~), 53.50 (CH~2~), 51.37 (CH~2~), 18.57 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~21~H~24~N~3~O \[M + H\]^+^, 334.1919; found, 334.1914.

### 6-Methyl-3-(piperidin-1-ylmethyl)-2-styrylimidazo\[1,2-*a*\]pyridine (**2h**) {#sec4.2.8}

Yield: (76 mg, 76%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.04 (s, 1H), 7.63 (d, *J* = 15.9 Hz, 1H), 7.57 (d, *J* = 7.5 Hz, 2H), 7.48 (d, *J* = 9.2 Hz, 1H), 7.37--7.34 (m, 2H), 7.22 (dd, *J* = 17.4, 11.7 Hz, 2H), 7.04 (dd, *J* = 9.2, 1.3 Hz, 1H), 3.80 (s, 2H), 2.43 (br s, 4H), 2.34 (s, 3H), 1.58--1.52 (m, 4H), 1.45 (br s, 2H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.63 (C), 142.05 (C), 137.69 (C), 130.21 (CH), 128.61 (CH), 128.17 (CH), 127.48 (CH), 126.59 (CH), 122.78 (CH), 121.05 (C), 118.52 (CH), 118.19 (C), 116.07 (CH), 54.49 (CH~2~), 51.74 (CH~2~), 25.95 (CH~2~), 24.41 (CH~2~), 18.41 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~22~H~26~N~3~ \[M + H\]^+^, 332.2127; found, 332.2125.

### 4-((6-Methyl-2-(phenylethynyl)imidazo\[1,2-*a*\]pyridin-3-yl)methyl)-morpholine (**2i**) {#sec4.2.9}

Yield: (68 mg, 68%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.02 (s, 1H), 7.58 (dd, *J* = 6.5, 3.1 Hz, 2H), 7.47 (d, *J* = 9.3 Hz, 2H), 7.36 (dd, *J* = 5.1, 1.8 Hz, 2H), 7.09 (dd, *J* = 9.2, 1.1 Hz, 1H), 3.92 (s, 2H), 3.71--3.68 (m, 4H), 2.54--2.52 (m, 4H), 2.37 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.39 (C), 132.17 (C), 132.07 (C), 131.90 (C), 131.63 (CH), 128.53 (CH), 128.44 (CH), 128.37 (CH), 123.03 (C), 122.28 (CH), 116.83 (CH), 92.77 (C), 82.66 (C), 66.92 (CH~2~), 53.50 (CH~2~), 52.00 (CH~2~), 18.43 (CH~2~). ESI-HRMS (*m*/*z*): calcd for C~21~H~22~N~3~O \[M + H\]^+^, 332.1763; found, 332.1755.

### 6-Methyl-2-(phenylethynyl)-3-(piperidin-1-ylmethyl)-imidazo-\[1,2-*a*\]pyridine (**2j**) {#sec4.2.10}

Yield: (78 mg, 79%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.10 (s, 1H), 7.60 (dd, *J* = 7.4, 2.0 Hz, 2H), 7.47 (d, *J* = 9.2 Hz, 1H), 7.39--7.35 (m, 3H), 7.08 (d, *J* = 9.2 Hz, 1H), 3.89 (s, 2H), 2.48 (br s, 4H), 2.37 (s, 3H), 1.60--1.55 (m, 4H), 1.47 (br s, 2H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.23 (C), 131.60 (CH), 128.39 (CH), 128.32 (CH), 128.05 (C), 123.75 (C), 123.18 (C), 122.64 (CH), 121.99 (C), 116.60 (CH), 92.45(C), 82.99 (C), 54.42 (CH~2~), 52.29 (CH~2~), 25.88 (CH~2~), 24.32 (CH~2~), 18.44 (CH~3~); ESI-HRMS (*m*/*z*): calcd for C~22~H~24~N~3~ \[M + H\]^+^, 330.1970; found, 330.1964.

### 2-Iodo-3-(pyrrolidin-1-ylmethyl)imidazo\[1,2-a\]pyridine (**2k**) {#sec4.2.11}

Yield: (71 mg, 72%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.34 (d, *J* = 6.9 Hz, 1H), 7.52 (d, *J* = 9.1 Hz, 1H), 7.19--7.14 (m, 1H), 6.79 (dd, *J* = 6.8, 0.9 Hz, 1H), 3.93 (s, 2H), 2.54 (t, *J* = 6.5 Hz, 4H), 1.78--1.74 (m, 4H); ^13^C NMR (101 MHz, CDCl~3~): δ 147.18 (C), 124.74 (CH), 124.50 (CH), 123.26 (C), 116.65 (CH), 112.18 (CH), 94.58 (C), 53.81 (CH~2~), 49.90 (CH~2~), 23.65 (CH~2~). ESI-HRMS (*m*/*z*): calcd for C~12~H~15~IN~3~ \[M + H\]^+^, 328.0311; found, 328.0338.

### 2-Iodo-6-methyl-3-(pyrrolidin-1-ylmethyl)imidazo\[1,2-*a*\]pyridine (**2l**) {#sec4.2.12}

Yield: (77 mg, 75%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.08 (s, 1H), 7.46 (d, *J* = 9.1 Hz, 1H), 7.04 (d, *J* = 9.2 Hz, 1H), 3.90 (s, 2H), 2.57 (br s, 4H), 2.37 (s, 3H), 1.79 (br s, 4H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.27 (C), 127.81 (CH), 123.02 (C), 122.00 (CH), 121.85 (C), 115.99 (CH), 94.14 (C), 53.90 (CH~2~), 49.92 (CH~2~), 23.65 (CH~2~), 18.33 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~13~H~17~IN~3~ \[M + H\]^+^, 342.0467; found, 342.0459.

### 2-Iodo-3-(piperidin-1-ylmethyl)imidazo\[1,2-a\]pyridine (**2m**) {#sec4.2.13}

Yield: (85 mg, 83%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.35 (d, *J* = 6.9 Hz, 1H), 7.51 (d, *J* = 9.1 Hz, 1H), 7.15 (dd, *J* = 9.0, 6.8, 1.2 Hz, 1H), 6.77 (dd, *J* = 6.8, 1.1 Hz, 1H), 3.73 (s, 2H), 2.39 (br s, 4H), 1.53--1.48 (m, 4H), 1.42 (br s, 2H); ^13^C NMR (101 MHz, CDCl~3~): δ 147.32 (C), 124.77 (CH), 124.70 (CH), 122.44 (C), 116.52 (CH), 112.03 (CH), 95.61 (C), 54.20 (CH~2~), 53.49 (CH~2~), 25.90 (CH~2~), 24.32 (CH~2~). ESI-HRMS (*m*/*z*): calcd for C~13~H~17~IN3 \[M + H\]^+^, 342.0467; found, 342.0449.

### 2-Iodo-6-methyl-3-(piperidin-1-ylmethyl)imidazo\[1,2-*a*\]pyridine (**2n**) {#sec4.2.14}

Yield: (93 mg, 87%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.11 (s, 1H), 7.45 (d, *J* = 9.2 Hz, 1H), 7.04 (d, *J* = 10.8 Hz, 1H), 3.73 (s, 2H), 2.43 (br s, 4H), 2.36 (s, 3H), 1.58--1.52 (m, 4H), 1.46 (br s, 2H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.46 (C), 127.84 (CH), 122.34 (CH), 121.96 (C), 121.75 (C), 115.95 (CH), 95.23 (C), 54.26 (CH~2~), 53.45 (CH~2~), 25.90 (CH~2~), 24.36 (CH~2~), 18.36 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~14~H~18~IN~3~ \[M + H\]^+^, 356.0624; found, 356.0624.

### 4-((2-Iodoimidazo\[1,2-*a*\]pyridin-3-yl)methyl)morpholine (**2o**) {#sec4.2.15}

Yield: (78 mg, 76%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.29 (d, *J* = 6.9 Hz, 1H), 7.54 (d, *J* = 9.1 Hz, 1H), 7.22--7.14 (m, 1H), 6.81 (t, *J* = 6.9, 1.0 Hz, 1H), 3.80 (s, 2H), 3.69--3.61 (m, 4H), 2.51--2.43 (m, 4H); ^13^C NMR (101 MHz, CDCl~3~): δ 147.47 (C), 124.97 (CH), 124.43 (CH), 121.42 (C), 116.81 (CH), 112.33 (CH), 96.04 (C), 66.88 (CH~2~), 53.21 (CH~2~), 53.09 (CH~2~). ESI-HRMS (*m*/*z*): calcd for C~12~H~15~IN~3~O \[M + H\]^+^, 344.0260; found, 339.0277.

### 4-((2-Iodo-6-methylimidazo\[1,2-*a*\]pyridin-3-yl)methyl)morpholine (**2p**) {#sec4.2.16}

Yield: (87 mg, 81%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.06 (s, 1H), 7.49 (d, *J* = 9.2 Hz, 1H), 7.08 (dd, *J* = 9.2, 1.1 Hz, 1H), 3.79 (s, 2H), 3.70--3.68 (m, 4H), 2.52--2.50 (m, 4H), 2.39 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.59 (C), 128.10 (CH), 122.10 (CH), 121.99 (C), 121.04 (C), 116.12 (CH), 95.56 (C), 66.89 (CH~2~), 53.26 (CH~2~), 53.05 (CH~2~), 18.35 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~13~H~17~IN~3~O \[M + H\]^+^, 358.0416; found, 358.0403.

### *N*-Ethyl-*N*-((2-iodoimidazo\[1,2-*a*\]pyridin-3-yl)methyl)ethanamine (**2q**) {#sec4.2.17}

Yield: (67 mg, 68%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.44 (d, *J* = 6.2 Hz, 1H), 7.53 (d, *J* = 9.1 Hz, 1H), 7.20--7.14 (m, 1H), 6.78 (t, *J* = 6.8 Hz, 1H), 3.89 (s, 2H), 2.55 (q, *J* = 6.9 Hz, 4H), 1.05 (t, *J* = 7.1 Hz, 6H); ^13^C NMR (126 MHz, CDCl~3~): δ 147.29 (C), 128.40 (C), 124.75 (CH), 116.54 (CH), 112.01 (CH), 95.29 (C), 48.35 (CH~2~), 46.34 (CH~2~), 11.50 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~12~H~17~IN~3~ \[M + H\]^+^, 330.0467; found, 330.0459.

### *N*-Ethyl-*N*-((2-iodo-6-methylimidazo\[1,2-*a*\]pyridin-3-yl)methyl)ethanamine (**2r**) {#sec4.2.18}

Yield: (77 mg, 75%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.20 (s, 1H), 7.44 (d, *J* = 9.2 Hz, 1H), 7.04 (d, *J* = 9.2 Hz, 1H), 3.87 (s, 2H), 2.61--2.56 (m, 4H), 2.35 (s, 3H), 1.08 (t, *J* = 7.1 Hz, 6H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.51 (C), 127.90 (C), 127.81 (C), 122.44 (CH), 115.95 (CH), 48.24 (CH~2~), 46.37 (CH~2~), 18.36 (CH~3~), 11.38 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~13~H~19~IN~3~ \[M + H\]^+^, 344.0624; found, 344.0616.

### *N*-((2-Iodo-6-methylimidazo\[1,2-*a*\]pyridin-3-yl)methyl)aniline (**2s**) {#sec4.2.19}

Yield: (87 mg, 80%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.91 (s, 1H), 7.48--7.45 (m, 1H), 7.28--7.25 (m, 2H), 7.04 (d, *J* = 9.1 Hz, 1H), 6.83 (t, *J* = 7.4 Hz, 1H), 6.79 (d, *J* = 7.7 Hz, 2H), 4.55 (s, 2H), 3.72 (br s, 1H), 2.31 (s, 3H); ^13^C NMR (126 MHz, CDCl~3~): δ 147.72 (C), 146.60 (C), 129.45 (2× CH), 128.25 (C), 122.67 (C), 122.24 (C), 121.67 (CH), 118.74 (CH), 116.33 (CH), 113.61 (2× CH), 94.57 (C), 39.50 (CH~2~), 18.25 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~15~H~15~IN~3~ \[M + H\]^+^, 364.0311; found, 364.0304.

### *N*-Benzyl-1-(2-iodo-6-methylimidazo\[1,2-*a*\]pyridin-3-yl)-methanamine (**2t**) {#sec4.2.20}

Yield: (100 mg, 88%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.95 (s, 1H), 7.43 (d, *J* = 9.2 Hz, 1H), 7.37--7.23 (m, 5H merged with CDCl~3~), 7.01 (dd, *J* = 9.2, 1.5 Hz, 1H), 4.06 (s, 2H), 3.83 (s, 2H), 2.32 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.42 (C), 139.82 (C), 128.45 (CH), 128.25 (CH), 127.81 (CH), 127.20 (CH), 123.46 (C), 121.98 (CH), 116.13 (CH), 94.11 (C), 53.09 (CH~2~), 43.13 (CH~2~), 18.23 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~16~H~16~IN~3~ \[M + H\]^+^, 378.0467; found, 378.0462.

### *N*-((2-Iodo-6-methylimidazo\[1,2-*a*\]pyridin-3-yl)methyl)prop-2-yn-1-amine (**2u**) {#sec4.2.21}

Yield: (85 mg, 87%); ^1^H NMR (400 MHz, CDCl~3~+ CD~3~OD): δ 8.04 (s, 1H), 7.38 (d, *J* = 9.2 Hz, 1H), 7.03 (d, *J* = 9.2 Hz, 1H), 4.13 (s, 2H), 3.38 (d, *J* = 2.3 Hz, 1H), 2.98 (s, 2H), 2.30 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.47 (C), 128.57 (CH), 122.68 (C), 121.92 (CH), 115.67 (CH), 93.81 (C), 81.23 (C), 72.40 (CH), 42.06 (CH~2~), 37.08 (CH~2~), 18.13 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~12~H~13~IN~3~ \[M + H\]^+^, 326.0154; found, 326.0156.

### *N*-((2-Phenylimidazo\[1,2-*a*\]pyridin-3-yl)methyl)propan-1-amine (**2w**) {#sec4.2.22}

Yield: (65 mg, 82%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.43 (d, *J* = 6.8 Hz, 1H), 7.76 (d, *J* = 7.4 Hz, 2H), 7.65 (d, *J* = 9.0 Hz, 1H), 7.50--7.47 (m, 2H), 7.41 (d, *J* = 7.2 Hz, 1H), 7.26--7.22 (m, 1H), 6.88--6.85 (m, 1H), 4.30 (s, 2H), 2.69 (t, *J* = 7.1 Hz, 2H), 1.58--1.53 (m, 2H), 0.93 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.38 (C), 134.40 (C), 128.80 (CH), 128.62 (CH~2~), 128.55(C), 127.87(C), 124.98 (CH), 124.81 (CH), 117.29 (CH), 112.15 (CH), 111.80 (CH), 51.03 (CH~2~), 42.63 (CH~2~), 22.60 (CH~2~), 11.68 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~17~H~20~N~3~ \[M + H\]^+^, 266.1657; found, 266.1643.

### 6-Chloro-2-iodo-3-(piperidin-1-ylmethyl)imidazo\[1,2-*a*\]pyridine (**2x**) {#sec4.2.23}

Yield: (81 mg, 72%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.37 (s, 1H), 7.78 (d, *J* = 7.8 Hz, 2H), 7.59 (d, *J* = 9.5 Hz, 1H), 7.53--7.49 (m, 2H), 7.45 (d, *J* = 6.8 Hz, 1H), 7.34 (d, *J* = 9.5 Hz, 1H), 4.88 (s, 2H), 3.47 (s, 3H); ^13^C NMR (126 MHz, CDCl~3~): δ 145.66 (C), 126.13 (CH), 123.08 (C), 122.61 (CH), 120.47 (C), 116.91 (CH), 96.06 (C), 54.25 (CH~2~), 53.52 (CH~2~), 25.88 (CH~2~), 24.29 (CH~2~). ESI-HRMS (*m*/*z*): calcd for C~13~H~16~ClIN~3~ \[M + H\]^+^, 376.0077; found, 376.0079.

General Procedure for C3-Methylene C--S Bond Formation of Imidazo\[1,2-*a*\]pyridine (**3**) {#sec4.3}
--------------------------------------------------------------------------------------------

A solution of 3-((benzyloxy) methyl)-2-phenylimidazo\[1,2-*a*\]pyridine (0.3 mmol) in dry DCM (2 mL) was stirred at 0 °C under a nitrogen atmosphere. BCl~3~ solution (1.0 M in methylene chloride) (0.42 mmol) was slowly added, and complex formation was confirmed by TLC. Then, reaction was transferred to rt and a solution of an organosulfur in DCM (0.9 mmol) was added, and reaction was continuously stirred for 2 h (reaction progress was monitored by TLC). After completion, the reaction was quenched by water to stop the reaction. The aqueous solution was extracted with DCM (3 × 10 mL). The combined organic layer was washed with brine, dried over anhydrous Na~2~SO~4~, and evaporated in vacuum. The residue was purified by a column (silica gel, 80/20 *n*-hexane/ethyl acetate) to give the desired product **3**.

### 2-Phenyl-3-((pyridin-2-ylthio)methyl)imidazo\[1,2-*a*\]pyridine (**3a**) {#sec4.3.1}

Yield: (65 mg, 68%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.49 (d, *J* = 4.4 Hz, 1H), 8.28 (d, *J* = 6.8 Hz, 1H), 7.88 (d, *J* = 7.3 Hz, 2H), 7.70 (d, *J* = 9.0 Hz, 1H), 7.57--7.49 (m, 3H), 7.43--7.39 (m, 1H), 7.27 (dd, *J* = 16.0, 5.2 Hz, 1H), 7.08 (dd, *J* = 6.7, 5.1 Hz, 1H), 6.89--6.87 (m, 2H), 5.07 (s, 2H); ^13^C NMR (101 MHz, CDCl~3~): δ 158.03 (C), 149.52 (CH), 145.21 (C), 144.70 (C), 136.26 (CH), 134.14 (C), 128.67 (CH), 128.53 (CH), 127.92 (CH), 124.74 (CH), 124.31 (CH), 122.67 (CH), 120.03 (CH), 117.54 (CH), 115.05 (C), 112.38 (CH), 24.64 (CH~2~). ESI-HRMS (*m*/*z*): calcd for C~19~H~16~N~3~S \[M + H\]^+^, 318.1065; found, 318.1027.

### 6-Methyl-2-phenyl-3-((*p*-tolylthio)methyl)imidazo\[1,2-*a*\]-pyridine (**3b**) {#sec4.3.2}

Yield: (73 mg, 71%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.80 (s, 1H), 7.68--7.64 (m, 2H), 7.56 (d, *J* = 9.2 Hz, 1H), 7.42--7.39 (m, 2H), 7.35--7.32 (m, 1H), 7.21 (d, *J* = 8.1 Hz, 2H), 7.08 (dd, *J* = 9.2, 1.4 Hz, 1H), 7.04 (d, *J* = 7.9 Hz, 2H), 4.50 (s, 2H), 2.35 (s, 3H), 2.31 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.65 (C), 144.23 (C), 137.82 (C), 134.20 (C), 132.41 (CH), 130.92 (C), 129.84 (CH), 128.46 (CH), 128.42 (CH), 127.78 (CH), 127.70 (CH), 121.93 (C), 121.68 (CH), 116.89 (CH), 114.93 (C), 30.25 (CH~2~), 21.05 (CH~3~), 18.40 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~22~H~21~N~2~S \[M + H\]^+^, 345.1425; found, 345.1419.

### 3-(((4-Methoxyphenyl)thio)methyl)-6-methyl-2-phenylimidazo-\[1,2-*a*\]pyridine (**3c**) {#sec4.3.3}

Yield: (81 mg, 75%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.83 (s, 1H), 7.73--7.70 (m, 2H), 7.59 (d, *J* = 9.2 Hz, 1H), 7.43 (dd, *J* = 10.2, 4.6 Hz, 2H), 7.36 (d, *J* = 7.3 Hz, 1H), 7.19--7.15 (m, 1H), 7.11 (dd, *J* = 9.1, 1.4 Hz, 1H), 6.92 (d, *J* = 7.7 Hz, 1H), 6.84--6.82 (m, 1H), 6.78 (dd, *J* = 8.3, 2.0 Hz, 1H), 4.57 (s, 2H), 3.70 (s, 3H), 2.36 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 159.95 (C), 144.12 (C), 135.98 (C), 129.90 (CH), 128.62 (CH), 128.42 (CH), 128.15 (C), 127.90 (CH), 123.52 (CH), 122.30 (C), 121.70 (CH), 122.26 (C), 116.82 (CH), 116.51 (CH), 114.52 (C), 113.48 (CH), 55.28 (OCH~3~), 29.47 (CH~2~), 18.44 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~22~H~21~N~2~OS \[M + H\]^+^, 361.1375; found, 361.1375.

### 6-Methyl-3-((octylthio)methyl)-2-phenylimidazo\[1,2-*a*\]pyridine (**3d**) {#sec4.3.4}

Yield: (70 mg, 64%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.94 (s, 1H), 7.81 (d, *J* = 7.2 Hz, 2H), 7.57 (d, *J* = 9.1 Hz, 1H), 7.49--7.45 (m, 2H), 7.39--7.35 (m, 1H), 7.09 (dd, *J* = 9.2, 1.4 Hz, 1H), 4.22 (s, 2H), 2.40 (s, 3H), 2.38 (d, *J* = 7.6 Hz, 2H), 1.48--1.40 (m, 2H), 1.31--1.18 (m, 12H), 0.88 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.34 (C), 136.23 (C), 134.43 (C), 128.62 (CH), 128.56 (CH), 127.78 (CH), 121.90 (CH), 116.87 (CH), 39.29 (CH~2~), 31.81 (CH~2~), 29.26 (CH~2~), 29.20 (CH~2~), 29.17 (CH~2~), 28.55 (CH~2~), 25.36 (CH~2~), 22.64 (CH~2~), 18.48 (CH~3~), 14.06 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~23~H~31~N~2~S \[M + H\]^+^, 367.2208; found, 367.1207.

### 6-Methyl-2-styryl-3-((*p*-tolylthio)methyl)imidazo\[1,2-*a*\]pyridine (**3e**) {#sec4.3.5}

Yield: (76 mg, 68%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.74 (s, 1H), 7.49 (d, *J* = 9.1 Hz, 1H), 7.44--7.37 (m, 3H), 7.34--7.30 (m, 2H), 7.24 (d, *J* = 7.2 Hz, 1H), 7.17 (d, *J* = 8.0 Hz, 2H), 7.08 (dd, *J* = 9.2, 1.4 Hz, 1H), 7.01 (d, *J* = 7.9 Hz, 2H), 6.55 (d, *J* = 15.8 Hz, 1H), 4.34 (s, 2H), 2.36 (s, 3H), 2.13 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.61 (C), 142.27 (C), 138.71 (C), 137.43 (C), 134.07 (CH), 130.35 (CH), 130.30 (C), 129.88 (CH), 128.48 (CH), 128.26 (CH), 127.45 (CH), 126.55 (CH), 121.67 (C), 121.34 (CH), 117.82 (CH), 116.95 (C), 116.50 (CH), 29.80 (CH~2~), 20.90 (CH~3~), 18.37 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~24~H~23~N~2~S \[M + H\]^+^, 371.1582; found, 371.1583.

### 6-Methyl-2-(phenylethynyl)-3-((*p*-tolylthio)methyl)imidazo-\[1,2-*a*\]pyridine (**3f**) {#sec4.3.6}

Yield: (70 mg, 63%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.80 (s, 1H), 7.48--7.45 (m, 3H), 7.35--7.33 (m, 3H), 7.21 (d, *J* = 8.1 Hz, 2H), 7.09 (dd, *J* = 9.2, 1.3 Hz, 1H), 6.99 (d, *J* = 7.9 Hz, 2H), 4.43 (s, 2H), 2.36 (s, 3H), 2.20 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 145.54 (C), 138.02 (C), 132.97 (CH), 132.17 (C), 131.62 (CH), 130.15 (C), 129.81 (CH), 128.39 (C), 128.33 (CH), 128.24 (CH), 125.58 (C), 123.02 (C), 122.51(CH), 121.61 (CH), 117.04 (CH), 95.42 (C), 92.53 (C), 29.53 (CH~2~), 20.99 (CH~3~), 18.40 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~24~H~21~N~2~S \[M + H\]^+^, 369.1425; found, 369.1424.

### 2-Iodo-3-(((4-methoxyphenyl)thio)methyl)-6-methylimidazo\[1,2-*a*\]pyridine (**3g**) {#sec4.3.7}

Yield: (101 mg, 82%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.77 (s, 1H), 7.45 (d, *J* = 9.2 Hz, 1H), 7.12 (d, *J* = 8.8 Hz, 2H), 7.04 (dd, *J* = 9.2, 1.5 Hz, 1H), 6.73 (d, *J* = 8.8 Hz, 2H), 4.20 (s, 2H), 3.76 (s, 3H), 2.35 (s, 3H); ^13^C NMR (126 MHz, CDCl~3~): δ 160.34 (C), 146.23 (C), 136.43 (CH), 127.81 (CH), 123.31 (C), 122.34 (C), 121.5 (C), 121.41 (CH), 116.32 (CH), 114.64 (CH), 95.51 (C), 55.35 (OCH~3~), 31.48 (CH~2~), 18.32 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~16~H~16~IN~2~OS \[M + H\]^+^, 411.0028; found, 411.0022.

### 2-Iodo-6-methyl-3-((*p*-tolylthio)methyl)imidazo\[1,2-*a*\]pyridine (**3h**) {#sec4.3.8}

Yield: (92 mg, 78%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.78 (s, 1H), 7.44 (d, *J* = 9.2 Hz, 1H), 7.14 (d, *J* = 8.0 Hz, 2H), 7.03 (d, *J* = 7.9 Hz, 3H), 4.27 (s, 2H), 2.33 (s, 3H), 2.30 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.30, 138.39, 133.71, 129.83, 129.68, 127.82, 122.35, 121.52, 121.39, 116.34, 95.50 (C), 30.81 (CH~2~), 21.15 (CH~3~), 18.31 (CH~3~) ESI-HRMS (*m*/*z*): calcd for C~16~H~16~IN~2~S \[M + H\]^+^, 395.0079; found, 395.0011.

### 3-(((2,6-Dichlorophenyl)thio)methyl)-2-iodo-6-methyl-imidazo-\[1,2-*a*\]pyridine (**3i**) {#sec4.3.9}

Yield: (107 mg, 80%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.94 (s, 1H), 7.46 (d, *J* = 9.2 Hz, 1H), 7.31 (d, *J* = 7.8 Hz, 2H), 7.21 (dd, *J* = 8.7, 7.3 Hz, 1H), 7.07 (dd, *J* = 9.2, 1.5 Hz, 1H), 4.33 (s, 2H), 2.40 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.49 (C), 142.67 (C), 130.98 (CH), 128.68 (CH), 128.04 (CH), 122.52 (C), 121.61 (CH), 120.73 (C), 116.31 (CH), 95.06 (C), 29.25 (CH~2~), 18.38 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~15~H~12~Cl~2~IN~2~S \[M + H\]^+^, 448.9143; found, 448.9142.

### 3-(((3-Fluorophenyl)thio)methyl)-2-iodo-6-methylimidazo\[1,2-*a*\]pyridine (**3j**) {#sec4.3.10}

Yield: (87 mg, 73%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.79 (s, 1H), 7.45 (d, *J* = 9.2 Hz, 1H), 7.18 (dd, *J* = 7.9, 5.5 Hz, 2H), 7.05 (d, *J* = 9.2 Hz, 1H), 6.90 (t, *J* = 8.4 Hz, 2H), 4.24 (s, 2H), 2.36 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 164.43 (C), 146.35 (C), 136.45(CH), 136.37 (CH), 127.96 (CH), 122.55 (C), 121.33 (CH), 121.03 (C), 116.44(CH) 116.29 (CH), 116.07 (CH), 95.73 (C), 31.10 (CH~2~), 18.32 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~15~H~13~FIN~2~S \[M + H\]^+^, 398.9828; found, 398.9932.

### 3-((Hexylthio)methyl)-2-iodo-6-methylimidazo\[1,2-*a*\]pyridine (**3k**) {#sec4.3.11}

Yield: (86 mg, 74%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.88 (s, 1H), 7.46 (d, *J* = 9.2 Hz, 1H), 7.04 (dd, *J* = 9.2, 1.4 Hz, 1H), 4.00 (s, 2H), 2.40--2.35 (m, 5H), 1.58--1.50 (m, 2H), 1.34--1.20 (m, 6H), 0.84 (t, *J* = 6.9 Hz, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.50 (C), 127.90 (CH), 122.32 (C), 121.67 (CH), 116.36 (CH), 94.83 (C), 31.39 (CH~2~), 31.29 (CH~2~), 29.68 (CH~2~), 28.52 (CH~2~), 25.66 (CH~2~), 22.51 (CH~2~), 18.35 (CH~3~), 14.00 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~15~H~22~IN~2~S \[M + H\]^+^, 389.0548; found, 389.0539.

### 2-Iodo-6-methyl-3-((pyridin-2-ylthio)methyl)imidazo\[1,2-*a*\]pyridine (**3l**) {#sec4.3.12}

Yield: (87 mg, 76%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.52 (d, *J* = 4.9 Hz, 1H), 8.05 (s, 1H), 7.51--7.49 (m, 1H), 7.42 (d, *J* = 9.2 Hz, 1H), 7.17 (d, *J* = 7.9 Hz, 1H), 7.04 (dd, *J* = 7.2, 5.1 Hz, 1H), 6.99 (d, *J* = 9.2 Hz, 1H), 4.82 (s, 2H), 2.28 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 157.67(C), 149.32 (CH), 146.33 (C), 136.31 (CH), 127.82 (CH), 122.85 (CH), 122.32 (C), 122.12 (CH), 121.69 (C), 120.14 (CH), 116.24 (CH), 95.16 (C), 24.73 (CH~2~), 18.32 (CH~3~); ESI-HRMS (*m*/*z*): calcd for C~14~H~13~IN~3~S \[M + H\]^+^, 381.9875; found, 381.9863.

General Procedure for C3-Methylene C--O Bond Formation of Imidazo\[1,2-*a*\]pyridine (**4**) {#sec4.4}
--------------------------------------------------------------------------------------------

A solution of 3-((benzyloxy) methyl)-2-phenylimidazo\[1,2-*a*\]pyridine (0.3 mmol) in dry DCM (2 mL) was stirred at 0 °C under a nitrogen atmosphere. BCl~3~ solution (1.0 M in methylene chloride) (0.42 mmol) was slowly added, and complex formation was confirmed by TLC. After that, reaction was allowed to raise temperature up to rt. Alcohol (500 μL) was added, and reaction was further stirred for another 2 h (reaction progress was monitored by TLC). After completion, the reaction was quenched by water to stop the reaction. The aqueous solution was extracted with DCM (3 × 10 mL). The combined organic layer was washed with brine, dried over anhydrous Na~2~SO~4~, and evaporated in vacuum. The residue was purified by a column (silica gel, 80/20 *n*-hexane/ethyl acetate) to give the desired product **4**.

### 3-(Methoxymethyl)-2-phenylimidazo\[1,2-*a*\]pyridine (**4a**)^[@ref12]^ {#sec4.4.1}

Yield: (51 mg, 72%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.22 (d, *J* = 6.9 Hz, 1H), 7.79 (dd, *J* = 5.2, 3.3 Hz, 2H), 7.70 (d, *J* = 9.1 Hz, 1H), 7.51--7.47 (m, 2H), 7.41 (d, *J* = 7.3 Hz, 1H), 7.30--7.27 (m, 1H), 6.89 (dd, *J* = 7.3, 6.3 Hz, 1H), 4.88 (s, 2H), 3.43 (s, 3H); ^13^C NMR (126 MHz, CDCl~3~): δ 145.64 (C), 145.23 (C), 134.00 (C), 128.78 (CH), 128.62 (CH), 128.07 (CH), 125.22 (CH), 124.37 (CH), 117.50 (CH), 116.79 (C), 112.54 (CH), 63.62 (CH~2~), 57.81 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~15~H~15~N~2~O \[M + H\]^+^, 239.1184; found, 239.1175.

### 3-(Methoxymethyl)-6-methyl-2-phenylimidazo\[1,2-*a*\]pyridine (**4b**) {#sec4.4.2}

Yield: (57 mg, 76%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.98 (s, 1H), 7.77 (d, *J* = 7.2 Hz, 2H), 7.60 (d, *J* = 9.1 Hz, 1H), 7.49--7.45 (m, 2H), 7.40 (d, *J* = 7.3 Hz, 1H), 7.12 (dd, *J* = 9.2, 1.3 Hz, 1H), 4.85 (s, 2H), 3.43 (s, 3H), 2.38 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.19 (C), 134.02 (C), 128.73 (CH), 128.59 (CH), 128.49 (CH), 127.99 (CH), 122.36 (C), 122.05 (CH), 116.77 (CH), 116.52 (C), 63.64 (CH~2~), 57.74 (CH~3~), 18.36 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~16~H~17~N~2~O \[M + H\]^+^, 253.1341; found, 253.1337.

### 6-Methyl-2-phenyl-3-(propoxymethyl)imidazo\[1,2-*a*\]pyridine (**4c**) {#sec4.4.3}

Yield: (55 mg, 66%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.99 (s, 1H), 7.79--7.77 (m, 2H), 7.56 (d, *J* = 9.2 Hz, 1H), 7.48--7.44 (m, 2H), 7.39--7.35 (m, 1H), 7.09 (dd, *J* = 9.2, 1.4 Hz, 1H), 4.88 (s, 2H), 3.50 (t, *J* = 6.6 Hz, 2H), 2.37 (s, 3H), 1.68--1.62 (m, 2H), 0.95 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 145.34 (C), 144.31 (C), 134.40 (C), 128.69 (CH), 128.53 (CH), 128.12 (CH), 127.82 (CH), 122.05 (CH), 122.03 (C), 116.83 (CH), 71.89 (CH~2~), 62.04 (CH~2~), 22.89 (CH~2~), 18.38 (CH~3~), 10.70 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~18~H~21~N~2~O \[M + H\]^+^, 281.1654; found, 281.1649.

### 6-Methyl-3-(propoxymethyl)-2-styrylimidazo\[1,2-*a*\]pyridine (**4d**) {#sec4.4.4}

Yield: (55 mg, 60%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.94 (s, 1H), 7.67 (d, *J* = 15.9 Hz, 1H), 7.58 (d, *J* = 7.4 Hz, 2H), 7.54 (d, *J* = 9.2 Hz, 1H), 7.38--7.34 (m, 2H), 7.28--7.25 (m, 1H), 7.17 (d, *J* = 15.9 Hz, 1H), 7.10 (dd, *J* = 9.2, 1.5 Hz, 1H), 4.88 (s, 2H), 3.43 (t, *J* = 6.6 Hz, 2H), 2.35 (s, 3H), 1.64--1.59 (m, 2H), 0.91 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.61 (C), 141.95 (C), 137.32 (C), 131.46 (CH), 129.08 (CH), 128.65 (CH), 127.79 (CH), 126.71 (CH), 122.17 (CH), 122.07 (C), 118.01 (C), 117.59 (CH), 116.16 (CH), 71.54 (CH~2~), 60.80 (CH~2~), 22.85 (CH~2~), 18.28 (CH~3~), 10.60 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~20~H~23~N~2~O \[M + H\]^+^, 307.1810; found, 307.1808.

### 3-(Methoxymethyl)-6-methyl-2-(phenylethynyl)imidazo\[1,2-*a*\]pyridine (**4e**) {#sec4.4.5}

Yield: (58 mg, 70%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.92 (s, 1H), 7.58 (dd, *J* = 6.5, 3.1 Hz, 2H), 7.48 (d, *J* = 9.2 Hz, 1H), 7.36--7.34 (m, 3H), 7.11 (dd, *J* = 9.2, 1.5 Hz, 1H), 4.89 (s, 2H), 3.36 (s, 3H), 2.35 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 144.60 (C), 131.69 (CH), 128.97 (CH), 128.82 (C), 128.52 (CH), 128.36 (CH), 122.91 (C), 122.82 (C), 121.97 (CH), 116.93 (CH), 92.72 (C), 82.33 (C), 62.98 (CH~2~), 57.43 (CH~2~), 18.28 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~18~H~17~N~2~O \[M + H\]^+^, 277.1341; found, 277.1326.

### 2-Iodo-3-(methoxymethyl)-6-methylimidazo\[1,2-*a*\]pyridine (**4f**) {#sec4.4.6}

Yield: (72 mg, 80%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.92 (s, 1H), 7.46 (d, *J* = 9.2 Hz, 1H), 7.06 (dd, *J* = 9.2, 1.4 Hz, 1H), 4.73 (s, 2H), 3.31 (s, 3H), 2.34 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.75 (C), 128.51(CH), 122.70 (C), 121.86 (C), 121.72 (CH), 116.29 (CH), 95.87 (C), 64.14 (CH~2~), 57.35 (CH~3~), 18.22 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~10~H~12~IN~2~O \[M + H\]^+^, 302.9994; found, 302.9953.

### 3-(Ethoxymethyl)-2-iodo-6-methylimidazo\[1,2-*a*\]pyridine (**4g**) {#sec4.4.7}

Yield: (65 mg, 69%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.96 (s, 1H), 7.46 (d, *J* = 9.2 Hz, 1H), 7.06 (dd, *J* = 9.2, 1.6 Hz, 1H), 4.78 (s, 2H), 3.53--3.47 (m, 2H), 2.35 (s, 3H), 1.20 (t, *J* = 7.0 Hz, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.55 (C), 128.40 (CH), 122.60 (C), 122.33 (C), 121.73 (CH), 116.28 (CH), 95.48 (C), 65.05 (CH~2~), 62.34 (CH~2~), 18.22 (CH~3~), 15.07 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~11~H~14~IN~2~O \[M + H\]^+^, 317.0151; found, 317.0150.

### 2-Iodo-6-methyl-3-(propoxymethyl)imidazo\[1,2-*a*\]pyridine (**4h**) {#sec4.4.8}

Yield: (72 mg, 73%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.97 (s, 1H), 7.46 (d, *J* = 9.2 Hz, 1H), 7.06 (dd, *J* = 9.2, 1.6 Hz, 1H), 4.78 (s, 2H), 3.39 (t, *J* = 6.6 Hz, 2H), 2.35 (s, 3H), 1.64--1.55 (m, 2H), 0.89 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.71 (C), 128.38 (CH), 122.55 (C),122.38 (C), 121.78 (CH), 116.27 (CH), 95.44 (C), 71.33 (CH~2~), 62.55 (CH~2~), 22.77 (CH~2~), 18.21 (CH~3~), 10.55 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~12~H~16~IN~2~O \[M + H\]^+^, 331.0307; found, 331.0308.

### 3-(Butoxymethyl)-2-iodo-6-methylimidazo\[1,2-*a*\]pyridine (**4i**) {#sec4.4.9}

Yield: (70 mg, 68%); ^1^H NMR (400 MHz, CDCl~3~): δ 7.96 (s, 1H), 7.45 (d, *J* = 9.2 Hz, 1H), 7.05 (dd, *J* = 9.2, 1.4 Hz, 1H), 4.77 (s, 2H), 3.42 (t, *J* = 6.6 Hz, 2H), 2.34 (s, 3H), 1.57--1.51 (m, 2H), 1.37--1.30 (m, 2H), 0.87 (t, *J* = 7.4 Hz, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 146.67 (C), 128.38 (CH), 122.55 (CH), 122.38 (C), 121.76 (CH), 116.24 (CH), 95.43 (C), 69.42 (CH~2~), 62.55 (CH~2~), 31.59 (CH~2~), 19.29 (CH~2~), 18.20 (CH~3~), 13.78 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~13~H~18~IN~2~O \[M + H\]^+^, 345.0464; found, 345.0465.

### 6-Bromo-3-(methoxymethyl)-2-phenylimidazo\[1,2-*a*\]pyridine (**4j**) {#sec4.4.10}

Yield: (68 mg, 71%); ^1^H NMR (400 MHz, CDCl~3~): δ 8.37 (s, 1H), 7.78 (d, *J* = 7.8 Hz, 2H), 7.59 (d, *J* = 9.5 Hz, 1H), 7.51 (t, *J* = 7.5 Hz, 2H), 7.45 (d, *J* = 6.8 Hz, 1H), 7.34 (d, *J* = 9.5 Hz, 1H), 4.88 (s, 2H), 3.47 (s, 3H); ^13^C NMR (126 MHz, CDCl~3~): δ 143.69 (C), 133.60 (C), 128.72 (CH), 128.57 (CH), 128.47 (C), 128.32 (CH), 124.60 (CH), 118.15 (CH), 117.25 (C), 107.21 (C), 63.53 (CH~2~), 58.04 (CH~3~). ESI-HRMS (*m*/*z*): calcd for C~15~H~14~BrN~2~O \[M + H\]^+^, 317.0290; found, 317.0287.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.9b00035](http://pubs.acs.org/doi/abs/10.1021/acsomega.9b00035).Copies of ^1^H and ^13^C NMR spectra ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b00035/suppl_file/ao9b00035_si_001.pdf))
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